Bruker Daltonics Announces Opening of maXis™ U.S. Demonstration Facility
News Mar 06, 2009
Bruker Daltonics has announced the opening of its Massachusetts demonstration facility for the ultra-high resolution time-of-flight (UHR-TOF) maXis™ mass spectrometer, as well as several maXis installations in top-tier U.S. life-science research laboratories.
The maXis, which Bruker will exhibit at PITTCON 2009 next week in Chicago, is said to be the only high-performance mass spectrometer available that simultaneously fulfills the two previously incompatible requirements in modern mass spectrometry of ultra-high mass resolution and fast UHPLC separations.
maXis is designed to deliver the combination of exceptional mass accuracy of better than 1 ppm, ultra-high mass resolving power of 40,000 to 60,000, dynamic range over 5 orders of magnitude, high m/z capabilities, stability allowing 1.5 mDa high-resolution extracted ion chromatograms (hrEIC), as well as outstanding sensitivity, all in MS and MS/MS mode and all maintained simultaneously even when coupled to separations fast liquid chromatography systems.
Bruker Daltonics claims that maXis is already well proven as an exceptional tool in quantitative proteomics, peptide and intact protein analysis in addition to small molecule identification using the unique SmartFormula™ 3D method for on-the-fly unambiguous molecular formula read-out, as co-developed with Pfizer, UK.
Professor Richard Caprioli of the Vanderbilt University School of Medicine plans to use the maXis in his research on changes in protein expression in various disease states.
Prof. Caprioli commented: “The performance of the maXis in our laboratory after the installation has shown that we will be able to achieve new levels of confidence in protein identification, and quantification of changes in protein expressions levels, as well as those for drugs and metabolites. We see this instrument as highly complementary to our extensive research program in profiling changes in protein expression levels using MALDI-TOF imaging.”
At PITTCON 2009, Professor Jonathan V. Sweedler from the University of Illinois at Urbana will present maXis data demonstrating the ability to characterize neuropeptides in samples as small as a single neuron with an unprecedented combination of very high resolution, high sensitivity and tandem MS capabilities.
About 422 million people around the world, including more than 30 million Americans, have diabetes. Obesity is the most significant risk factor for type 2 diabetes. yet about 30 percent of obese people do not develop type 2 diabetes or other metabolic conditions. New research aims to understand on a cellular level, how this separation occurs.READ MORE
Measuring hand grip can help identify youths who could benefit from lifestyle changes, says new research. While other studies have shown that muscle weakness as measured by grip strength is a predictor of unhealthy outcomes - including cardiovascular and metabolic diseases - this is the first to do so for adolescent health over time.READ MORE